skip to main content
Idioma:
Resultados 1 2 3 next page
Refinado por: assunto: Science & Technology remover assunto: Tumors remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers
Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers
Material Type:
Artigo 		Adicionar ao Meu Espaço

Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers

IMHOF, Anna ; BRUNNER, Philippe ; MARINCEK, Nicolas ; BRIEL, Matthias ; SCHINDLER, Christian ; RASCH, Helmut ; MÄCKE, Helmut R ; ROCHLITZ, Christoph ; MÜLLER-BRAND, Jan ; WALTER, Martin A

Journal of clinical oncology, 2011-06, Vol.29 (17), p.2416-2423 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
2
Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers
Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers
Material Type:
Artigo 		Adicionar ao Meu Espaço

Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers

VILLARD, Linda ; ROMER, Anna ; BRIEL, Matthias ; WALTER, Martin A ; MARINCEK, Nicolas ; BRUNNER, Philippe ; KOLLER, Michael T ; SCHINDLER, Christian ; NG, Quinn KT ; MÄCKE, Helmut R ; MÜLLER-BRAND, Jan ; ROCHLITZ, Christoph

Journal of clinical oncology, 2012-04, Vol.30 (10), p.1100-1106 [Periódico revisado por pares]

Alexandria, VA: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
3
Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours
Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours
Material Type:
Artigo 		Adicionar ao Meu Espaço

Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours

Romer, A. ; Seiler, D. ; Marincek, N. ; Brunner, P. ; Koller, M. T. ; Ng, Q. K. T. ; Maecke, H. R. ; Müller-Brand, J. ; Rochlitz, C. ; Briel, M. ; Schindler, C. ; Walter, M. A.

European journal of nuclear medicine and molecular imaging, 2014-02, Vol.41 (2), p.214-222 [Periódico revisado por pares]

Berlin/Heidelberg: Springer Berlin Heidelberg

Texto completo disponível

Citações Citado por
4
Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study
Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study

Marincek, Nicolas ; Jörg, Ann-Catherine ; Brunner, Philippe ; Schindler, Christian ; Koller, Michael T ; Rochlitz, Christoph ; Müller-Brand, Jan ; Maecke, Helmut R ; Briel, Matthias ; Walter, Martin A

Journal of translational medicine, 2013-01, Vol.11 (1), p.17-17, Article 17 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível

Citações Citado por
5
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)

Rochlitz, C. ; Ruhstaller, T. ; Lerch, S. ; Spirig, C. ; Huober, J. ; Suter, T. ; Bühlmann, M. ; Fehr, M. ; Schönenberger, A. ; von Moos, R. ; Winterhalder, R. ; Rauch, D. ; Müller, A. ; Mannhart-Harms, M. ; Herrmann, R. ; Cliffe, B. ; Mayer, M. ; Zaman, K.

Annals of oncology, 2011-01, Vol.22 (1), p.80-85 [Periódico revisado por pares]

Oxford: Elsevier Ltd

Texto completo disponível

Citações Citado por
6
Toxic Encephalopathy Induced by Capecitabine
Toxic Encephalopathy Induced by Capecitabine
Material Type:
Artigo 		Adicionar ao Meu Espaço

Toxic Encephalopathy Induced by Capecitabine

Niemann, B. ; Rochlitz, C. ; Herrmann, R. ; Pless, M.

Oncology, 2004-01, Vol.66 (4), p.331-335 [Periódico revisado por pares]

Basel, Switzerland: Karger

Texto completo disponível

Citações Citado por
7
[90Yttrium-DOTA]-TOC Response Is Associated With Survival Benefit in Iodine-Refractory Thyroid Cancer : Long-term Results of a Phase 2 Clinical Trial
[90Yttrium-DOTA]-TOC Response Is Associated With Survival Benefit in Iodine-Refractory Thyroid Cancer : Long-term Results of a Phase 2 Clinical Trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

[90Yttrium-DOTA]-TOC Response Is Associated With Survival Benefit in Iodine-Refractory Thyroid Cancer : Long-term Results of a Phase 2 Clinical Trial

ITEN, Fabienne ; MULLER, Beat ; SCHINDLER, Christian ; RASCH, Helmut ; ROCHLITZ, Christoph ; OERTLI, Daniel ; MAECKE, Helmut R ; MULLER-BRAND, Jan ; WALTER, Martin A

Cancer, 2009-05, Vol.115 (10), p.2052-2062 [Periódico revisado por pares]

Hoboken, NJ: Wiley-Blackwell

Texto completo disponível

Citações Citado por
8
SMAD7 is a prognostic marker in patients with colorectal cancer
SMAD7 is a prognostic marker in patients with colorectal cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

SMAD7 is a prognostic marker in patients with colorectal cancer

Boulay, Jean‐Louis ; Mild, Gabriele ; Lowy, Adam ; Reuter, Juergen ; Lagrange, Magali ; Terracciano, Luigi ; Laffer, Urban ; Herrmann, Richard ; Rochlitz, Christoph

International journal of cancer, 2003-04, Vol.104 (4), p.446-449 [Periódico revisado por pares]

New York: Wiley Subscription Services, Inc., A Wiley Company

Texto completo disponível

Citações Citado por
9
Current Concepts of Treatment Strategies in Advanced or Recurrent Ovarian Cancer
Current Concepts of Treatment Strategies in Advanced or Recurrent Ovarian Cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Current Concepts of Treatment Strategies in Advanced or Recurrent Ovarian Cancer

Salzberg, Marc ; Thürlimann, Beat ; Bonnefois, Hervé ; Fink, Daniel ; Rochlitz, Christoph ; von Moos, Roger ; Senn, Hansjörg

Oncology, 2005-01, Vol.68 (4-6), p.293-298 [Periódico revisado por pares]

Basel, Switzerland: Karger

Texto completo disponível

Citações Citado por
10
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
Material Type:
Artigo 		Adicionar ao Meu Espaço

Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?

Regan, M.M. ; Pagani, O. ; Walley, B. ; Torrisi, R. ; Perez, E.A. ; Francis, P. ; Fleming, G.F. ; Price, K.N. ; Thürlimann, B. ; Maibach, R. ; Castiglione-Gertsch, M. ; Coates, A.S. ; Goldhirsch, A. ; Gelber, R.D.

Annals of oncology, 2008-07, Vol.19 (7), p.1231-1241 [Periódico revisado por pares]

Oxford: Elsevier Ltd

Texto completo disponível

Citações Citado por
Resultados 1 2 3 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.